Investor Relations

Investor Overview Image

Prothena Corporation plc (Nasdaq: PRTA) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel antibodies that are directed towards diseases that involve protein misfolding or cell adhesion. These potential therapies have a number of indications including AL and AA forms of amyloidosis (NEOD001), Parkinson’s disease and related synucleinopathies (PRX002), and novel cell adhesion targets involved in autoimmune diseases and cancers (PRX003).

NASDAQ: PRTA
$ 20.90
0.33 (1.60%)

Day High: 20.98
Day Low:  20.03
Volume:    90,000
4:00 PM ET
Oct 24, 2014

Delayed ~20 min., by eSignal.

Press Releases

Aug 26, 2014
Aug 18, 2014